|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A large number of epidemiological studies in ethnically diverse populations show that lipoprotein(a) [Lp(a)] levels above 30-50 mg/dL are significantly associated with calcific aortic valve stenosis, although less so in African Americans.
|
30616181 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis.
|
31766423 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Background Apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio and lipoprotein(a) (Lp[a]) are associated with aortic valve stenosis (AVS) disease progression.
|
31407609 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis.
|
30702993 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High lipoprotein(a) levels are observationally and causally, from human genetics, associated with increased risk of cardiovascular disease including myocardial infarction and aortic valve stenosis.
|
31111240 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)], a major carrier of oxidized phospholipids (OxPL), is associated with an increased incidence of aortic stenosis (AS).
|
31047003 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
External validation confirmed the association of the LPA risk allele with risk of AVS (OR 1.37; 95%CI 1.27-1.47), again with a higher effect size in those without CAD.
|
30482443 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
High lipoprotein(a) is associated with increased risk of myocardial infarction and aortic valve stenosis.
|
31272552 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study.
|
30099661 |
2019 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] has been classified as the most prevalent genetic risk factor for coronary artery disease and aortic valve stenosis.
|
30087087 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] has been associated with AVS in recent genetic studies.
|
29614432 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
New evidence supports a causal role for lipoprotein (a) in atherosclerotic cardiovascular disease and aortic valve stenosis.
|
29609758 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, some biomarkers including plasma level of lipoprotein(a), F-sodium fluoride, brain natriuretic peptides and high-sensitivity cardiac troponin can be or are very close to be used for the clinical management of patients with aortic valve stenosis.
|
29194051 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To replicate the association between LPA variants with AS and identify subgroups who are at higher risk of developing AS.
|
29128868 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disorders including coronary heart disease and calcific aortic valve stenosis.
|
29852400 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of Lipoprotein(a)-Levels in Patients ≥70 Years of Age With Versus Without Aortic Valve Stenosis.
|
29954600 |
2018 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
APOE ε2 is a strong genetic determinant of low lipoprotein(a) concentrations but does not modify the causal association of lipoprotein(a) with myocardial infarction or aortic valve stenosis.
|
28651346 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In particular, lipoprotein(a) [Lp(a)] and apolipoproteins (Apo) are associated with AS, but it is unknown whether these associations differ among phenotypes.
|
29246959 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) is associated with adverse cardiovascular risk and is elevated in patients with aortic stenosis.
|
28704465 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting.
|
28068801 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is the strongest independent genetic risk factor for both myocardial infarction and aortic stenosis.
|
28059953 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lipoprotein(a) [Lp(a)] is a proatherogenic lipoprotein associated with coronary heart disease, ischemic stroke, and more recently aortic stenosis and heart failure (HF).
|
28554015 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis.
|
28729361 |
2017 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated lipoprotein(a) levels represent a genetically determined risk factor for myocardial infarction (MI) and aortic valve stenosis (AVS).
|
26656145 |
2016 |
|
Aortic Valve Stenosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific aortic valve stenosis, but no approved specific therapy exists to substantially lower Lp(a) concentrations.
|
27665230 |
2016 |